Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | NQO1 | P15559 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012663 | 0.83 | CYP3A4 (0.49) | CYP3A4TP53NQO1LTA4HHSD17B10 | |
| SCHEMBL23558 | 0.80 | HTR3E (0.53) | CYP3A4MIFHSD17B10MAPTALDH1A1 | |
| SCHEMBL6119686 | 0.80 | CYP2D6 (0.39) | CYP3A4TP53MIFHSD17B10GABRA1 | |
| SCHEMBL631317 | 0.80 | NQO1 (0.58) | CYP3A4TP53MIFNQO1LTA4H | |
| SCHEMBL1399693 | 0.79 | MAOB (0.53) | MIFLMNACYP1A2CYP2C19 | |
| SCHEMBL29444412 | 0.78 | MIF (0.50) | CYP3A4TP53MIFMAPTALDH1A1 | |
| SCHEMBL5532468 | 0.77 | TP53 (0.53) | CYP3A4TP53NQO1LTA4HHSD17B10 | |
| SCHEMBL5796149 | 0.76 | MIF (0.44) | CYP3A4TP53MIFHTTGABRA1 | |
| SCHEMBL9857139 | 0.75 | MIF (0.47) | CYP3A4TP53MIFHSD17B10GABRA1 | |
| SCHEMBL28866376 | 0.75 | MIF (0.52) | CYP3A4TP53MIFHSD17B10HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10059674-B2 | Design, synthesis, and biological evaluation of 1-methyl-1, 4-dihyrdoindeno[1,2-C]pyrazole analogues as potential anticaner agents targeting tubulin colchicine binding site | ACT PHARMA CO., LTD. (CN) | 2018-08-28 | — | — | US | claimed |
| US-20170327468-A1 | DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF 1-METHYL-1, 4-DIHYRDOINDENO[1,2-C]PYRAZOLE ANALOGUES AS POTENTIAL ANTICANER AGENTS TARGETING TUBULIN COLCHICINE BINDING SITE | JOYOCHEM CO., LTD (CN) | 2017-11-16 | — | — | US | claimed |
| US-10059674-B2 | Design, synthesis, and biological evaluation of 1-methyl-1, 4-dihyrdoindeno[1,2-C]pyrazole analogues as potential anticaner agents targeting tubulin colchicine binding site | ACT PHARMA CO., LTD. (CN) | 2018-08-28 | — | — | US | disclosed |
| US-20170327468-A1 | DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF 1-METHYL-1, 4-DIHYRDOINDENO[1,2-C]PYRAZOLE ANALOGUES AS POTENTIAL ANTICANER AGENTS TARGETING TUBULIN COLCHICINE BINDING SITE | JOYOCHEM CO., LTD (CN) | 2017-11-16 | — | — | US | disclosed |
| US-7816390-B2 | N-substituted tricyclic 3-aminopyrazoles as anti-mitotic tubulin polymerization inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| US-20080227821-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS ANTI-MITOTIC TUBULIN POLYMERIZATION INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-09-18 | — | — | US | disclosed |
| WO-2008094896-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS ANTI-MITOTIC TUBULIN POLYMERIZATION INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-07 | — | — | WO | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| EP-1682516-A2 | IMMOBILIZED N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES FOR THE IDENTIFICATION OF BIOMOLECULAR TARGETS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-26 | — | — | EP | disclosed |
| US-20050130910-A1 | Immobilized N-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-16 | — | — | US | disclosed |
| WO-2005049579-A2 | IMMOBILIZED N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES FOR THE IDENTIFICATION OF BIOMOLECULAR TARGETS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-02 | — | — | WO | disclosed |
| EP-1506175-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | US | disclosed |
| WO-2003097609-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | disclosed |
| US-4112100-A | INCREASING THE ENDOGENOUS PRODUCTION OF PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10059674-B2 | Design, synthesis, and biological evaluation of 1-methyl-1, 4-dihyrdoindeno[1,2-C]pyrazole analogues as potential anticaner agents targeting tubulin colchicine binding site | TUBA1C, TUBB1, TUBB3 | CYP3A4 106/4885TP53 108/4885MIF 1953/4885 |
| US-20080227821-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS ANTI-MITOTIC TUBULIN POLYMERIZATION INHIBITORS | TUBB3, TUBB1, TUBA1C | CYP3A4 2393/4885TP53 206/4885MIF 2420/4885 |
| US-20170327468-A1 | DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF 1-METHYL-1, 4-DIHYRDOINDENO[1,2-C]PYRAZOLE ANALOGUES AS POTENTIAL ANTICANER AGENTS TARGETING TUBULIN COLCHICINE BINDING SITE | TUBA1C, TUBB1, TUBB3 | CYP3A4 106/4885TP53 108/4885MIF 1953/4885 |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | CYP3A4 2935/4885TP53 109/4885MIF 2942/4885 |
| US-20050130910-A1 | Immobilized N-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets | ABAT, NAT1, AADAC | CYP3A4 14/4885TP53 1853/4885MIF 620/4885 |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | CYP3A4 2964/4885TP53 94/4885MIF 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.